BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 24342458)

  • 1. The effect of gradual increment in rhG-CSF dose on stem cell yields in patients with multiple myeloma mobilized with intermediate dose cyclophosphamide plus rhG-CSF.
    Hacıoğlu S; Sarı I; Doğu MH; Keskin A
    Transfus Apher Sci; 2014 Feb; 50(1):71-4. PubMed ID: 24342458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
    Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
    Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.
    Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V
    Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
    Shimura Y; Kuroda J; Uchiyama H; Kawata-Iida E; Tsutsumi Y; Nagoshi H; Mizutani S; Yamamoto-Sugitani M; Matsumoto Y; Kobayashi T; Horiike S; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
    J Clin Apher; 2013 Oct; 28(5):368-73. PubMed ID: 23804501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
    Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
    J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
    Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
    Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The possible cost effectiveness of peripheral blood stem cell mobilization with cyclophosphamide and the late addition of G-CSF.
    Min YJ; Kim SW; Suh C; Park J; Kim HJ; Kim JG; Kim TW; Lee JH; Kim SB; Lee KH; Lee JS; Kim WK; Kim SH
    J Korean Med Sci; 2000 Feb; 15(1):49-52. PubMed ID: 10719808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective.
    Bargetzi MJ; Passweg J; Baertschi E; Schoenenberger A; Gwerder C; Tichelli A; Burger J; Mingrone W; Herrmann R; Gratwohl A; Wernli M
    Bone Marrow Transplant; 2003 Jan; 31(2):99-103. PubMed ID: 12621490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
    J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
    Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF.
    Ozcelik T; Topcuoglu P; Beksac M; Ozcan M; Arat M; Biyikli Z; Bakanay SM; Ilhan O; Gurman G; Arslan O; Demirer T
    Bone Marrow Transplant; 2009 Dec; 44(12):779-83. PubMed ID: 19597420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
    Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
    Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF.
    Demirer T; Ayli M; Ozcan M; Gunel N; Haznedar R; Dagli M; Fen T; Genc Y; Dincer S; Arslan O; Gürman G; Demirer S; Ozet G; Uysal A; Konuk N; Ilhan O; Koc H; Akan H
    Br J Haematol; 2002 Feb; 116(2):468-74. PubMed ID: 11841454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients.
    Meehan KR; Slack R; Gehan E; Herscowitz HB; Areman EM; Ebadi M; Cairo MS; Lippman ME
    J Hematother Stem Cell Res; 2002 Apr; 11(2):415-21. PubMed ID: 11983113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
    Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H
    Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
    Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
    J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
    Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
    Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.